Drug Profile

Research programme: yellow fever therapeutics - Collaborations Pharmaceuticals

Alternative Names: Pyrazolesulfonamide derivative

Latest Information Update: 02 Mar 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

15 Feb 2022 Yellow fever therapeutics - Collaborations Pharmaceuticals is available for licensing as of 07 Feb 2022. https://www.collaborationspharma.com/pipeline
07 Feb 2022 Collaborations Pharmaceuticals files for patent protection for Yellow fever therapeutics before February 2022 (Collaborations Pharmaceuticals pipeline, February 2022)
07 Feb 2022 Preclinical trials in Yellow fever in USA (unspecified route) before February 2020 (Collaborations Pharmaceuticals pipeline, February 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com